Research

Progress in the battle against HIV/AIDS only happens through years of scrupulous research and experimentation; think of this as the process for “moving the needle” forward. HIV Cure Foundation matches philanthropic contributions to fund innovations that build on decades of progress towards ending the HIV/AIDS epidemic. Just as yesterday’s clinical trials improve the lives of people currently living with HIV/AIDS, today’s hard work will one day make HIV/AIDS a relic of history... HIV Cure Foundation’s mission is to ensure progress continues.

HIV Cure Foundation (HCF) was founded by a group of passionate individuals determined to find a cure for the disease that has plagued the world since 1981. HCF was created for the individuals who need #theHIVCure more than anything. HCF filed for a 501(c)3 determination from the IRS on November 2, 2020.

Moving the needle of progress requires identifying and funding innovative, science-based research. HIV Cure Foundation is committed to providing the funds for clinical research that will provide relief from taking daily medications, long term side effects and the stigma of HIV/AIDS.

As of March 2021, HIV Cure Foundation announced the financial support of their first human clinical trial: “Phase 1 Study to Evaluate the Safety of Genetically Modified, Autologous T Cells in Participants With HIV That is Well-Controlled on Antiretroviral Therapy” This research is one of many crucial avenues of experimentation in the ongoing fight against HIV/AIDS. Should this research prove effective, it would provide clinical participants a functional cure, meaning the virus is not completely eliminated by the body's immune system but can be controlled without medication. After FDA approval, people living with HIV would no longer require their antiretroviral therapy, no longer be able to progress to AIDs or transmit the virus to others.

Maryland-based, American Gene Technologies is a clinical-stage gene and cell therapy company that has developed AGT103-T, a single dose, autologous cell therapy intended to cure HIV. Greenlighted by the FDA, human clinical trials are currently underway in Washington, DC at Georgetown University and Washington Health Institute. This study is registered with The NIH National Library of Medicine Clinical Trials Registry.

HOW

this study works

Identify an HIV-infected individual that is well-controlled on antiretroviral therapy (ART) for at least two years.
Collect HIV-specific white blood cells (T-cells) from the patient (leukapheresis).
Perform an eleven-day process that stimulates and genetically modifies HIV-specific T-cells by permanently installing three mechanisms of action to make the cells immune from the HIV virus.
Cryopreserve the T-cells while performing quality control testing.
Return the modified cells to the patient by an infusion.

WHAT

does this trial mean for an individual infected with HIV?

Immediate— If AGT103-T is successful in demonstrating safety and efficacy, it will validate that a broadly available cure for HIV is possible.
Long term— If AGT103-T is approved by the FDA, patients who are living with HIV, but well controlled on ART, may be functionally cured. This means they would no longer require their antiretroviral therapy, no longer be able to progress to AIDs or transmit the virus to other people, and would potentially be free from long-term side effects or ongoing medical costs.

WHY

are we asking for your financial commitment?

To help accelerate research; this and other research that could potentially eliminate HIV/AIDS.
To be a part of improving the quality-of-life for HIV-infected individuals.
To help end the HIV/AIDS epidemic once and for all!

How your gift today can help move the needle:

HIV Cure Foundation is currently reviewing several promising research trials; the American Gene project is the first to receive a funding grant. Their Phase 1 human clinical trial just began and will cost upwards of $2.7 million. The treatment fees associated with a single patient are $150,000. This will possibly cure one patient by extracting, genetically modifying and reinfusing their HIV-specific cells! As more patients are introduced into the study, the cost will decrease incrementally per participant Your gift today can help us move the needle for a potential cure.

Research is extremely expensive;
the value of a human life is priceless.

Your donation in any amount will help make life-changing research possible.

#theHIVCure is on the horizon, we invite you to give generously today:
• any portion of one patient’s clinical trial ($500...$2,500...$25,000...any amount)
• an entire patient ($150,000)
• an entire trial! ($1mil+)

Click Here to Donate TODAY

Research

How your gift today can help move the needle:

Research is extremely expensive; the value of a human life is priceless.

Research is extremely expensive;
the value of a human life is priceless.